The market can be unforgiving... and very forgetful...
09/02/05 - Reduces Transdermal Drug Delivery Times by 70% 01/03/05 - Demonstrates fine control over drug delivery rates 10/03/05 - University Tests Confirm Time-Based Drug Delivery Capability 17/03/05 - Presentation to the 39th Annual Conference ASCC 16/05/05 - Presentation to the Australasian College of Dermatologists 20/07/05 - Accelerates Skin Cancer Drug Absorption by 900% 16/08/05 - To Present at World Congresses on Inflammation & Pain 16/09/05 - Results of Study - Transdermal Delivery of Voltaren 11/11/05 - Vaccine Patch Matches Injections in 2nd Phase Pilot Study 05/12/05 - 100 Fold Increase in Transdermal Delivery of Naltrexone 06/12/05 - Presentation to Australasian Pharmaceutical Science Assoc 06/12/05 - Full Copy of Presentation to Aust Pharmaceutical Science Assoc 13/12/05 - 75 Fold Increase in Cortisone Delivery Through-the-Skin 09/02/06 - Lodges patent over new energy driven drug delivery process 06/04/06 - Drug Delivery Technology to be Presented at Conference in France 26/06/06 - OBJ's Technology Enhances Follicle Drug Delivery 19/09/06 - Dermaportation Demonstrates Lasting Effects 07/12/06 - Reduces Time to Onset in Successful Clinical Trial 11/01/07 - Dermaportation Study to be published by prestigious journal 11/07/07 - Positive Results for Delivery of Therapeutic Peptide 17/03/09 - OBJ Data Presentation in France 06/04/09 - Technology Testing Update 08/07/09 - eM-Patch Tooth Strip 22/07/09 - eM-Patch Permeation Study 01/10/09 - US Study Results 17/12/09 - Pharmaceutical Journal Publication 13/05/10 - FIM Technology Platform
Notice the clear trend in those positive announcements becoming less frequent and more conservative as partner interest increases?
Another small reminder of why some of us are invested in OBJ...
Some International Presentations not announced to the market:
2007 - Dermaportation treated skin is more permeable to Voltaren Emulgel at World Congress on Inflammation, Copenhagen.
2007 - Increased transdermal delivery of local anaesthetics by the novel penetration enhancement technology Dermaportation - Pharmaceutical Science World Congress in Amsterdam.
2007 - Enhanced transdermal delivery of a dipeptide by Dermaportation - 4th International Peptide Symposium, Cairns, Qld.
2008 - Enhanced transdermal delivery of a dipeptide by inductive energy - PPP Conference, La Grande Motte, France
2009 - Electromagnetophoresis - 3rd Symposium and Skin Forum 10th Conference, Versailles, France
2009 - Electromagnetic field energy as a skin penetration enhancer - Australasian Pharmaceutical Science Association Conference, Hobart, Tasmania.
2010 - Magnetic enhanced transdermal drug delivery - PPP Conference, La Grande Motte, France
I was recently advised by the administrators of a new Australian Biotechnology investment site that OBJ Limited were omitted from the list of stocks as they "don't have any published Peer Reviewed articles"
Some Peer Reviewed Scientific Journal Articles on OBJ Technologies not announced to the market
For those who suggest that OBJ may choose to hide any bad news, history may suggest to be careful what you wish for, even when the timing of a GFC is not favorable...
Bad news released to the market? Most definitely, but not once... 08/09/08 - Shareholder Update "In January 2008, the Company commenced an in vitro proof-of-concept (POC) program at the University of Queensland (UQ) to validate its DP and ETP delivery platforms for pharmaceutical applications. This program included a series of in vitro skin diffusion studies to evaluate and select susceptible drugs and then optimize the formulation and magnetic fields before progressing to in vivo POC in animals and/or humans.... However, the improvement was less than the results previously achieved at Curtin..."
Not twice... 30/09/08 - 2008 Annual Report "In September 2008, the Company released a shareholder update advising that the technology POC program had found initial evidence..."
Not three times (just for those who missed the first 2008 Annual Report... 24/10/08 - Annual Report 2008 "In September 2008, the Company released a shareholder update advising..."
Not four times... 18/12/08 - Shareholder Update "In September 2008 the Company released a shareholder update advising that the in vitro proof-of-concept (POC) program conducted at the University of Queensland (UQ) under the supervision of Professor Michael Roberts to validate the OBJ technology had found initial evidence supporting enhanced transdermal delivery of Naltrexone by the Dermaportation (DP) platform. However, the improvement in in vitro drug diffusion was less than results previously achieved..."
... But at least fives times this one piece of bad news was highlighted to the market... 06/04/09 - Technology Testing Update "In September 2008, the Company reported that it had sought assistance from respected transdermal experts in Australia and Europe, to better understand the reasons behind the inter-laboratory differences in the levels of enhancement achieved when testing the Company’s technologies at different Universities."
Judging by history of repeatedly highlighting bad news and omitting the good stuff, god help us all if even one of OBJ's partner programs was to ever be abandoned...
The answer to why any company would do this is quite simple, imo - They are very serious about the science and their confidence for successfully commercializing the technology doesn't require any desperate measures... leave this to all the other companies who don't have the significant advantage of selecting whomever they wish to partner... Imo.
November 2011 - Q&A with the MD at the AGM not announced to the market Q: Has any company walked away from negotiations or turned down the company recently, past 12 months? Glyn:No programs have been abandoned.
Q: Is fmcg #1 still interested in progresing with OBJ in respect of its OTC product? As announced to the market discussions were continuing and another party was interested, so when would OBJ consider taking it to the other party? Glyn: We are working aggressively with both companies over different catogories, no programs have been abandoned!
Breaking the Barriers of Drug Permeation via the Skin Nowadays, the transdermal route has become one of the most successful and innovative focus for research in drug delivery, with around 40% of the drug candidate being under clinical evaluation related to transdermal or dermal systems. The technology has a proven record of FDA approval since the first transdermal patch was approved in 1981. The market for transdermal products has been in a significant upward trend and this is likely to continue for the foreseeable future. An increasing number of TDD products continue to deliver real therapeutic benefit to patients around the world. More than 35 TDD products have now been approved for sale in the US, and approximately 16 active ingredients have been approved for use globally. - Breaking the Barriers of Drug Permeation via the Skin
Remember, there's a reason so few active agents can be successfully delivered via traditional transdermal delivery methods...
Limitations for a drug candidate to be incorporated into a transdermal delivery system are: • Higher molecular weight candidates (>500Da) fail to penetrate the stratum corneum. • Drugs with very low or high partition coefficient fail to reach systemic circulation. • High melting drugs, due to their low solubility both in water and fat. Such candidates cannot be delivered across the skin without effectively making suitable modifications in the conventional transdermal delivery systems.
... until now!
OBJ - Method and Apparatus for Enhanced Transdermal Diffusion Suitable active agent(s) that can be delivered by the invention include any active agent(s) exhibiting negative magnetic susceptibility and any active agent(s) having therapeutic, cosmetic, restorative or beneficial properties when administered transdermally, perdermally and interdermally
Classes of active agents, include, for example, proteins, peptides, nucleotides, anti-obesity drugs, corticosteroids, analgesics, anti-fungal agents, oncology therapies, cardiovascular agents, anti-inflammatory agents, non-steroidal anti-inflammatory agents, anti-airhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, anti-hypertension agents, anti-neoplasric agents, immunosuppressants, anti-thyroid agents, antiviral agents, sedatives, astringents, beta-adrenoceptor blocking agents, diuretics, muscle reactants, prostaglandins, sex hormones, anti-allergic agents, stimulants, vasodilators, xanthenes, antioxidants, vitamins, nutrients, skin restorative agents and those active agents delivered as nutraceuticals, cosmeceutical or cosmetics to or through a dermal surface.
The following provides an illustrative list of some of the active agents that may be used such as with the apparatus of the present invention:
a. Parasympatholytics scopolamine, and benactyzine and the like; b. cholinergics such as physostigmine, nicotine and the like; c. monoamine oxidase inhibitors such as tranylcypromine, selegiline and the like; d. sympathomimetics such as ephedrine, D-norpseudoephedrine, salbutamol, fenfluramine and the like;
Edrenergic blockers and anticympathotonics such as propanolol, timolol, bupranolol, clonidine, dihydroergotamine, naphazoline and the like; f . Hi Receptor Antagonists such as: terfenadine and the like; g. HJ Receptor Antagonists such as: Famotidine/ Cimetidine and
Ranitidine Hydrochloride and the like; h. antispasmodics such as Hyoscine Butylbromide, Hyos?ne
Hydrobromide, atropine, methscopolamine bromide and the like; i. beta-adrenergic agents such as: Antagonists - Esmolol hydrochloride. Propranolol HQ and Atenolol, (ß-adrenergic agonist); agonists — DL isoproterenol hydrochloride and the like; j. diuretic effects agents such as Frusemide and the like; k. anti-arrhythmic agents such as; Amiodarone hydrochloride,
Verapamil hydrochloride, Procainamide hydrochloride, Disopyramide, Flecainide acetate, and Lignocaine hydrochloride and the like;
Adrenergic stimulants such as: Adrenalin, Metaraminol bitartrate,
Dobutamine hydrochloride, Isoprenaline hydrochloride. Noradrenaline acid tartrate and Dopamine hydrochloride and the like; m. antimigraine preparations such as: Dihydroergotamine mesylate, mazindol, phentermine and Sumatriptan succinate and the like; n. other cardiovascular agents such as: Indomethacin Methyldopate HCl, Hydralazine hydrochloride, isosorbide dinitrate, Clonidine hydrochloride, Verapamil, Glyceril Trinitrate, Rauwolfia alkaloids, organic nitrates, pentaerythritotetranitrate, Diazoxide and Sodium nitroprusside and the like; o. antihistamines (e.g., diphenhydramine, clemastine, terfenadine) p. sedatives and hypnotics such as: chlorpromazine HCl, clozapine, mesoridazine, metiapine, reserpine, thioridazine Midazolam, Paraldehyde, propofol, codeine, phenobarbital, sodium pentobarbital, sodium secobarbital, chlordiazepoxide, diazepam, meprobamate and tema2epam and the like; q. anti-anxiety agents such as: Diazepam, Droperidol, dopamine antagonist such as Haloperidol decanoate, and the like; r. anti-depressants such as desipramine hydrochloride and the like; s. psychotropic agents such as 5-hydroxytryptamine receptor antagonists (e.g. ondanstetron, sumatriptan, naratryptan), ergotamine tartrate plus caffeine, or methylsegide and the like; t. movement disorder agents such as Benztropine mesylate,
Phenytoin sodium/ Phenobarbitone sodhum and Clona2«pam and the like; u. anti-Parkinson agents such as L-DOPA and the like; v. narcotic analgesics such as Fentanyl citrate, Sufentanyl, Alphentanyl, Morphine Sulphate, dihydrocodienone, hydromorphine, meperidine, Pethidine hydrochloride,
Phenoperidine hydrochloride, Papaveretum, Methadone hydrochloride and Buprenophine hydrochloride and the like; w. narcotic antagonists such as naltrexone and naloxone and the like; x. non-steroidal agents such as salicylates, acetaminophen, d- propoxyphene, Indomethatin, Naproxen and Ketorolac trometamol and the like; y. other Analgesics such as (cyclooxygenase inhibitors), fenamic acids, Piroxicam, COX-2 inhibitors, diclofenac), rofecoxib, and Ibuprofren and the like; z. hormonal preparations such Menopausal Gonadotrophin, Growth Hormone - Somatropin, Desmopressin acetate, Bromocriptine mesylate, Octreotide, Insulin, Glibenclamide, Metformin hydrochloride, Glipizide and Tolbutamide and the like; aa. agents acting on the uterus such as: Oxytocin, and the like;
Steroids such as sulfonamides, triamcinolone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylpredmsolone, prednisolone, prednisone sodium phosphate, fiuorometholone, rimexolone, medrysone alcohol, 11 - desoxcortisol, and anecortave acetate and the like cc. testosterone and testosterone propionate, progesterone and estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol, and the like; dd. prostaglandins such as Ritodrine hydrochloride and Salbutamol sulfate and the like; ee. antitussives such as dextromethorphan, noscapine and the like; ff. anti-inflammatory agents such as hormonal agents, c?obetasol, dexamethasone, acetyl salicylic acid, glycyrrhizic add or glycyrrhetic acid, hydrocortisone, prednisolone, prednisone, non- hormonal agents, allopurinol, aspirin, indometha?n, phenylbutazone and the like; gg. bronchospasm relaxants such as Aminophylline, Theophylline, Salbutamol sulfate, Orciprenaline sulfate, Ipratropium bromide, Fenoterol hydrobromide, Terbutaline sulfate and Adrenaline acid tartrate and the like hh. antimalarials such as 4-aminoquinolines, 8-aminoquinoIines,
Pyrimethamine and the like; ii. antibiotics such as the cephalosporins, chlotanphenical, gentamicin, Kanamycin A, Kanamydn B, the peni?llins, ampicillin, streptomycin A, antimycin A, chloropamtheniol, metromidazole, oxytetracycline penicillin G, the tetacyclines and the like; jj. sexual dysfunction agents such as sildenafil ?trate, tadalafil and vardenafil and the like;
Cytotoxic drags such as thiofcepa, chlorambucil, cyclophosphamide, melphalan, methotrexate and the like;Cardio- ionatropic agents such as Digoxin and the like;
Vitamins and nutrients including essential amino acids and the like; mm. electrolyte replacements such as potassium chloride and the like; nn. peptides with either therapeutic benefit or cosmetic benefit comprising between two and 20 amino acid residues, preferably, between three and 10 amino add residues (cosmetic peptides such as palmitoyl pentapepu'de or argireline and the like will — preferably they have beneficial effect on skin cells eg whitening, free-radical scavenging, anti-aging, stimulation of collagen synthesis, moisturizing, antimicrobial, anti-inflammatory, or anti- irritant and the like; oo. astringents, such as clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate and the like; pp. antioxidants or free-radical scavengers, such as ascorbic acid, its fatty esters and phosphates, tocopherol and its derivatives, N- acetyl cysteine, sorbic acid and lipoic acid and the like; qq. anti-acne agents, such as salicylic acid and benzoyl peroxide; rr. antimicrobial or antifungal agents such as caprylyl glycol, triclosan, phenoxyethanol, erythromycin, tolnaftate, nystatin or clotrimazole; ss. chelating agents, such as EDTA and the like; tt. topical analgesics, such as benzocaine, tetracaine, lidocaine or procaine and the like; uu. central analgesics such as fentanyl, sufentanil and the like; vv. antirheumatics such as indomethadn, piroxicam, lornoxicam ww. anti-aging/anti-wrinkle agents, such as retinoids or hydroxy acids;
Skin lightening agents, such as licorice, ascorbyl phosphates, hydroquinone or kojic acid and the like; yy. skin-conditioning agents such as humectants, including miscellaneous and occlusive and the like; zz. ant?rritants, such as cola, bisabolol, aloe vera or panrhenol and the like; aaa. anti-cellulite agents, such as caffeine and other xanthines and the like; bbb. humectants, such as alkylene polyols or hyaluronic acid and the like;
Emollients, such as oily esters or petrolatum and the like; ddd. sun protecting agents (organic or inorganic), such as avobeitzone, oxybenzone, octylmethoxytinnamate, titanium dioxide or zinc oxide; eee. exfoliating agents (chemical or physical), such as N-acetyl glucosamine, mannose phosphate, hydroxy acids, lactobionic acid, peach kernels, or sea salts and the like; and fff . self-tanning agents, such as dihydroxyacetone.WIPO: OBJ Limited - Method and Apparatus for Enhanced Transdermal Diffusion
"Suitable active agent(s) that can be delivered by the invention include any active agent(s) exhibiting negative magnetic susceptibility and any active agent(s) having therapeutic, cosmetic, restorative or beneficial properties when administered transdermally, perdermally and interdermally"
OBJ Price at posting:
1.5¢ Sentiment: LT Buy Disclosure: Held
(20min delay)